JMJD2C-Mediated Long Non-Coding RNA MALAT1/MicroRNA-503-5p/SEPT2 Axis Worsens Non-Small Cell Lung Cancer

Researchers explored the downstream mechanism of Jumonji domain containing protein 2C (JMJD2C) in NSCLC from the long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1/microRNA-503-5p/septin 2 axis.
[Cell Death & Disease]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

LUMAKRAS® (Sotorasib) Receives Approval in Japan for Patients with KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer

Amgen announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer that has progressed after systemic anticancer therapy.
[Amgen, Inc.]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Notch Pathway Inhibition Mediated by Arsenic Trioxide Depletes Tumor Initiating Cells in Small Cell Lung Cancer

Researchers demonstrated that As2O3 had a remarkable inhibitory effect on tumor initiating cells of small cell lung cancer both in vitro and in vivo, and the mechanism might have involved the down-regulation of Notch pathway
[Molecular Biology Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

PLOD3 Regulates the Expression of YAP1 to Affect the Progression of Non-Small Cell Lung Cancer via the PKCδ/CDK1/LIMD1 Signaling Pathway

Silencing procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD3) promoted the cleavage ofprotein kinase C δ (PKCδ) in a caspase-dependent manner to generate a catalytically active fragment cleaved PKCδ, enhanced phosphorylation levels of CDK1, and LIMD1 but suppressed nuclear translocation of YAP1.
[Laboratory Investigation]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Breaking the Crosstalk of the Cellular Tumorigenic Network by Low-Dose Combination Therapy in Lung Cancer Patient-Derived Xenografts

Selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib.
[Communications Biology]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Integrated Single-Cell RNA Sequencing Analysis Reveals Distinct Cellular and Transcriptional Modules Associated with Survival in Lung Cancer

Researchers established a multi-omics atlas, integrating 52 single-cell RNA sequencing and 2342 public bulk RNA sequencing. They investigated their differences in genetic amplification, cellular compositions, and expression modules.
[Signal Transduction and Targeted Therapy]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

EDDM3A Drives Gastric Cancer Progression by Promoting HIF-1α-Dependent Aerobic Glycolysis

Researchers showed that the expression of EDDM3A was significantly upregulated in gastric cancer tissues and its upregulation correlates with poorer survival in patients with gastric cancer.
[Oncogenesis]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.
[Rubius Therapeutics, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

On Target Laboratories Completes ELUCIDATE Phase III Clinical Trial Investigating the Use of CYTALUX™ (Pafolacianine) Injection in Cancer in the Lung

On Target Laboratories, Inc., announced the completion of the Phase III, randomized, multi-center, single dose, open-label ELUCIDATE (Enabling LUng Cancer IDentification Using FolATE Receptor Targeting) Trial, which investigated the use of CYTALUX (pafolacianine) injection in patients scheduled to undergo thoracic surgery for confirmed or suspected cancer in the lung.
[On Target Laboratories, Inc. (CISION PR Newswire)]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Role, Molecular Mechanism and the Potential Target of Breast Cancer Stem Cells in Breast Cancer Development

Scientists discuss the latest developments in breast cancer stem cells (BCSCs) research, focusing on the analysis of specific markers, critical signaling pathways that maintain the stemness of BCSCs, such as NOTCH, Wnt/β-catenin, STAT3, Hedgehog, and Hippo-YAP signaling.
[Biomedicine & Pharmacotherapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-Class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.
[Fate Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share